Business Description
Arcutis Biotherapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US03969K1088
Description
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.32 | |||||
Equity-to-Asset | 0.26 | |||||
Debt-to-Equity | 2.32 | |||||
Debt-to-EBITDA | -0.9 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -2.73 | |||||
Beneish M-Score | 9.96 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 4.7 | |||||
3-Year EPS without NRI Growth Rate | 0.2 | |||||
3-Year FCF Growth Rate | -4 | |||||
3-Year Book Growth Rate | -47.3 | |||||
Future 3-5Y Total Revenue Growth Rate | 84.72 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 13.62 | |||||
9-Day RSI | 27.36 | |||||
14-Day RSI | 36.09 | |||||
6-1 Month Momentum % | 291.14 | |||||
12-1 Month Momentum % | -33.31 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 7.08 | |||||
Quick Ratio | 6.8 | |||||
Cash Ratio | 5.83 | |||||
Days Inventory | 784.4 | |||||
Days Sales Outstanding | 102.46 | |||||
Days Payable | 931.55 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -30.7 | |||||
Shareholder Yield % | -6.54 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 91.63 | |||||
Operating Margin % | -404.49 | |||||
Net Margin % | -439.79 | |||||
FCF Margin % | -415.2 | |||||
ROE % | -231.9 | |||||
ROA % | -73.48 | |||||
ROIC % | -830.65 | |||||
ROC (Joel Greenblatt) % | -2208.12 | |||||
ROCE % | -72.42 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 9.54 | |||||
PB Ratio | 9.21 | |||||
Price-to-Tangible-Book | 9.96 | |||||
EV-to-EBIT | -4.02 | |||||
EV-to-EBITDA | -4.04 | |||||
EV-to-Revenue | 15.46 | |||||
EV-to-FCF | -3.72 | |||||
Price-to-Net-Current-Asset-Value | 10.59 | |||||
Price-to-Net-Cash | 42.35 | |||||
Earnings Yield (Greenblatt) % | -24.88 | |||||
FCF Yield % | -25.41 |